Interestingly, high DNM1L expression was associated with a poor prognosis in patients with osteosarcoma but predicted better outcomes in patients with rhabdomyosarcoma, suggesting a possible sarcoma subtype–dependent role for mitochondrial fission in the therapeutic response. The gene discussed is DNM1L; the disease is rhabdomyosarcoma.